The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Orphan drugs and the NHS: should we value rarity?
Open accessAbstract
Cost effectiveness plays an important part in current decisions about the funding of health technologies. Drugs for rare disease (orphan drugs) are often expensive to produce and, by definition, will benefit only small numbers of patients. Several countries have put measures in place to safeguard research and development of orphan drugs, but few get close to meeting the cost effectiveness criteria for funding by healthcare providers. We examine the justifications for special status for rare diseases and ask whether the cost effectiveness of drugs for rare or very rare diseases should be treated differently from that of other drugs and interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A rational framework for decision making by the National Institute for Clinical Excellence (NICE)
Claxton, K., Sculpher, M., & Drummond, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09832-x · Cited by 456
Self-citation
Cited by
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661
Pricing and reimbursement of orphan drugs: the need for more transparency
Simoens, S. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-42 · Cited by 260
Optimizing Value From Cardiac Rehabilitation
Leggett, L. E., Hauer, T., Martin, B.-J., Manns, B., Aggarwal, S., Arena, R., Austford, L. D., Meldrum, D., Ghali, W., Knudtson, M. L., et al. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.05.015 · Cited by 34
Metadata
- Authors
- McCabe, C., Claxton, K., & Tsuchiya, A.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2005-10-27
- Volume
- 331
- Issue
- 7523
- Pages
- 1016-1019
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2092086072
- Cited by
- 229
- References
- 1
- FWCI
- 21.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orphan drugs and the NHS: should we value rarity? https://app.cochat.ai/papers/10.1136/bmj.331.7523.1016
- The paper
- McCabe, C., Claxton, K., & Tsuchiya, A. (2005). Orphan drugs and the NHS: should we value rarity? BMJ. https://doi.org/10.1136/bmj.331.7523.1016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.